As a direct result of the outbreak of the coronavirus disease (COVID-19) and due to circumstances beyond our control, DIA has decided to postpone the Digital Technology in Clinical Trials Meeting originally scheduled for March 30-31 to a date later in the year.
The health and safety of our entire DIA family remains our top priority. Following recent reports from the World Health Organization (WHO) and escalating health concerns around the spread of the disease, our decision to postpone, while unfortunate, is necessary and unavoidable.
DIA’s mission – to work across the healthcare continuum to ensure patients receive the therapies they need – is essential during times like these. DIA acknowledges the time and effort that has gone into speaker and attendee planning and preparing for DIA’s Digital Technology in Clinical Trials Meeting, and trusts that everyone will understand our need to respond to currently evolving health concerns in a responsible manner.
You will not be required to re-register for the Digital Technology in Clinical Trials Meeting, your current registration will be transferred to the new date once confirmed. More details will be provided in the coming weeks. For more information, please review this list of Frequently Asked Questions
We regret any inconvenience caused by this change of schedule and appreciate your understanding in this matter.
Thank you for your continued support of DIA and our global mission
Digital technology is transforming the drug development process. The rise of wearable and mobile technologies along with cloud technology, Artificial Intelligence and related platforms, now enable the collection of frequent, specific, and multidimensional data throughout the length of trials. These technologies have the potential to enable innovative trial designs, improve the patient experience, act as recruitment and retention tools, and establish novel end points in clinical studies.
With these technologies, large amounts of data are collected. How to best address evaluating fit-for-purpose, standardization, ethical concerns, and regulatory approaches, are key issues to address in the digital era.
DIA’s Digital Technology in Clinical Trials Conference will bring together thought leaders from regulatory agencies, biotech, pharma, patients, and academia to discuss the latest advances, challenges, and forward-thinking approaches for implementing digital technology to improve clinical trials. While the conference will focus on the impact of digitalization in clinical trials today, we will make time to explore future applications and how they may enable the clinical trials of tomorrow.
Co-Sponsored with ePRO Consortium – Critical Path Institute
What will you learn?
Get your burning questions answered at our new conference on digital technology in clinical trials. Check out our infographic to see which specific questions will be answered.View Infographic
On Demand Content Preview Webinar:
So, My Fitbit is Clinical Trial Grade, Right?
The promise of wearables and sensor data includes collecting data that demonstrates new investigational products are safe and efficacious and/or that fewer site visits are required; thus, making clinical trials more efficient, less intrusive, and less expensive. This presentation will break down the elements of wearables selection, evaluation, and inclusion in clinical trials, allowing you to better understand the support structure required for wearable sensor use. This presentation will also touch on integration touch points between wearables and other eClinical systems.Learn More
Who should attend?
Executive, Leadership, and Management Professionals from Biotechnology, Pharmaceutical, Device, CRO, Regulatory Agency, and Academic Research Sponsors involved in:
- Business Development
- Clinical Trial Design and Development
- Study Endpoint Development
- Clinical Research, Operations, Site Selection, and Management
- Research and Development
- Clinical Monitoring and Oversight
- Quality Management
- Contracts Management
- Clinical Data Management
- Data and Biostatistical Sciences
- Health Economics and Outcomes Research
- eClinical Technology and Solutions
- Digital Strategies and Technologies
- Data Analytics, Strategy, and Technology
- Information Technology, Systems, and Programming
- Regulatory Affairs
- Patient Engagement, Recruitment, and Retention
- Patient Advocacy, Partnerships, and Services
- Legal and Compliance
- Ethics, IRBs
- Medical Affairs and Communications
- Articulate and evaluate applications of digital technologies in clinical trials to: improve patient experience, ensure that trial endpoints are clinically meaningful and represent improved patient outcomes, improve trial design, facilitate the conduct and operation of clinical trials, and facilitate the collection and use of quality data for clinical study and regulatory decision-making.
- Describe related policy, legal, scientific, and regulatory concerns
- Discuss the evolving roles, skills, and qualifications of medical product professionals in the application and use of these technologies in clinical trials.
Paul O'Donohoe, MS • Scientific Lead, eCOA and Mobile Health
Medidata Solutions, United States
Sonya L. Eremenco, MA • Associate Director, PRO Consortium, and Acting Director, ePRO Consortium
Critical Path Institute, United States
Lauren Oliva, PharmD, RPh • Global Regulatory Policy Lead, New Technologies
Biogen, United States
Keith Wenzel • Senior Director, Scientific Data Organization
Parexel, United States
Julie Dietrich, MS • Vice President, Clinical Operations
Genfit Corp, United States
Harlan M. Krumholz, MD • Harold H. Hines, Jr. Professor of Medicine and Director, Center for Outcomes Res
Yale University, United States
Jonathan Raymond Andrus, PhD, MBA, MS • Chief Business Officer
Clinical Ink, United States
Doug Peddicord, PhD • Executive Director
Association of Clinical Research Organizations (ACRO), United States
Casey Orvin • President
Society for Clinical Research Sites, United States
Jennifer Goldsack, MA, MBA, MS • Executive Director
Digital Medicine Society (DiMe), United States
Jules T Mitchel, PhD, MBA • President
Target Health LLC, United States
J. Jason Lundy, PhD • Principal
Outcometrix, United States
Paul Upham • Head, Smart Devices
Roche / Genentech, United States
Kristen Valdes • Founder and Chief Executive Officer
B.Well Connected Health, United States
Dan Tierno, MA, MBA • Associate Director, Project and Portfolio Management
Daiichi Sankyo, Inc, United States
Matthew Diamond, MD, PhD • Medical Officer, Digital Health, Office of the Center Director, CDRH
FDA, United States
Adria Martig, PhD • Senior Director, Research Programs
Parkinson's Foundation, United States
Preconference Short Courses
On Demand Content Preview Webinar
So, My Fitbit is Clinical Trial Grade, Right?